GRTX — Galera Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.81m
- $148.39m
Annual income statement for Galera Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 70.6 | 73.4 | 51.2 | 49.3 | 20.2 |
| Operating Profit | -70.6 | -73.4 | -51.2 | -49.3 | -20.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -74.2 | -80.5 | -62.3 | -59.1 | -19.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -74.2 | -80.5 | -62.2 | -59.1 | -19 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -74.2 | -80.5 | -62.2 | -59.1 | -19 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -74.2 | -80.5 | -62.2 | -59.1 | -19 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.98 | -3.12 | -2.3 | -1.27 | -0.251 |